Five antibodies that fight Covid-19 discovered by Singapore's defence R&D organisation



The DSO National Laboratories team that worked on the development of the Covid-19 antibodies. PHOTO: DSO NATIONAL LABORATORIES

() PUBLISHED JUN 17, 2020, 12:02 PM SGT

Timothy Goh (mailto:timgoh@sph.com.sg)

SINGAPORE - Five antibodies which could potentially neutralise the virus that causes Covid-19 have been discovered by scientists at DSO National Laboratories, Singapore's defence research and development organisation.

Known as neutralising antibodies, they prevent the virus from infecting a patient's cells by binding with the part of the virus that is needed to enter the cells.

DSO announced on Wednesday (June 17) that since March, its researchers have screened hundreds of thousands of antibodies produced by cells of the human immune system in blood samples taken from recovered Covid-19 patients.

The samples were provided by the National Centre for Infectious Diseases and the Singapore General Hospital.

Dr Conrad Chan, principal research scientist and laboratory director (applied molecular technology) at DSO, said: "Administration of an antibody obtained from a recovered individual transfers that person's protection to the recipient, enabling any patient to better fight the infection and recover faster."

He added that as antibodies remain in the system for close to a month, they can also be used to prevent infection.

The first two neutralising antibodies were discovered on March 19 and 30 using a screening technique that had been developed in collaboration with the National University of Singapore's (NUS) Life Sciences Institute and the NUS Yong Loo Lin School of Medicine over the last five years.

Covid-19: Don't miss the latest on the outbreak and its impact

Stay in the know with e-mail alerts

Enter your e-mail

By signing up, you agree to our Privacy Policy and Terms and Conditions.

The technique, which involves the use of a live virus, is part of DSO's "Antibodies on Demand" strategy to counter novel infectious disease outbreaks. It allows for quick identification of neutralising antibodies and saves more time and manpower compared with conventional methods.

Dr Chan said: "The Ministry of Defence and DSO recognised that a novel pandemic would have a severe impact on Singapore and we wanted to, very early on, look for ways to protect the population... We narrowed in on antibodies from recovered patients as the best strategy to develop a therapeutic that would protect against a novel outbreak of disease."

Related Story	>
Doctors in Singapore eager for full results of drug trial that promises to cut Covid-19 deaths	í
Related Story	>
Singapore to start human clinical trials for potential Covid-19 treatment	
	、

Related Story

Sign up

DSO will also be bringing together a Singapore-based consortium comprising government agencies, research institutes and biomedical companies to quickly advance the development of the antibodies.

Dr Brendon Hanson, principal research scientist and project lead, said: "We are trying to tap all the expertise that has been developed in Singapore over the last few years so we can have a completely in-Singapore capability to bring an antibody from the research phase into the clinical phase, to be able to treat Covid-19 infection (here)."

Human trials for the most promising antibody of the five, known as AOD01, will likely commence in the upcoming months, pending approval from the Health Sciences Authority.

How do antibodies work







When a person is infected with the virus that causes Covid-19, the virus tries to multiply in the body's cells.

🎢 Antibody

B cells in the human immune system produce antibodies to block the infection.

3 Some antibodies bind themselves to the virus to prevent it from infecting healthy cells, and also signal other white blood cells to destroy it. The antibodies produced remain in the recovered patient's blood as protection from future infections.

ANTIBODY TREATMENT FOR COVID-19 VIRUS STRAINS

Antibody treatment begins with screening and taking the most potent antibodies from a recovered patient through blood samples.





4

Special cells that are genetically engineered to produce large quantities of antibodies are cultured.



3

The antibodies are then purified from the cell culture and prepared for injection in an infected patient for antibody therapy, or

4

This speeds up recovery for infected patients, and blocks new infections. given preventatively to a healthy person.





NOTES:

 A single injection of antibodies will last about a month in the body. Antibody drugs are already being used to treat cancer and autoimmune diseases.

 However, antibody treatment does not yet exist in the market for Covid-19.

DSO added that the necessary manufacturing capabilities to scale up therapeutic antibody treatment for patients are in place, pending the successful completion of clinical trials.

Dr Hanson said: "When clinical trials are completed and successful, we hope to be able to quickly translate the positive results from the laboratory into a viable effective treatment for Covid-19."



DSO chief executive officer Cheong Chee Hoo said: "While still in its experimental phase, this discovery is an important milestone in Singapore's fight against and managing life with Covid-19 until a vaccine is available.

"With an effective treatment, people will be more assured as they can be treated immediately and can expect to make a faster recovery. This prevents our healthcare system from being overwhelmed, and normalises our daily routine as we continue to live and interact as a community."

Antibodies screening -A difficult process



Screening and isolating potent antibodies for therapy is both time consuming and requires a lot of manpower.





Only less than 0.01 per cent of the approximately 100,000 B cells in each blood sample produces the antibodies capable of effectively neutralising the virus.

Less than 0.01%





With DSO's screening technique, **ANTIBODIES ON DEMAND**, B cells can be quickly screened for the best antibodies. This technique reduces both the time and manpower required.



More antibodies can thus be found and quickly translated into safe and effective treatments for Covid-19 patients in less time.

2020 TIMELINE

March



DSO screens hundreds of thousands of B cells, isolating and testing the first two antibodies within a month. These antibodies can safely and efficiently combat the virus that causes Covid-19 and its key mutations. May DSO identifies three more effective antibodies, bringing the total to five. June

Further testing is conducted on the lead antibody, AODO1, for clinical trials.

Pending approval by the Health Sciences Authority, clinical trials for AODO1 will begin in the coming months.

Source: DSO NATIONAL LABORATORIES STRAITS TIMES GRAPHICS

RELATED STORIES:



48-year-old man who recovered from Covid-19 dies after fainting at temporary housing site for migrant workers



Experts warn against excessive mixing and mingling during phase 2 of S'pore's reopening



South Korea fights rise in imported Covid-19 cases; authorities warn 2nd wave already hit capital area